HAE Earnings Date: Nov 5, 2026 (Estimated) — Haemonetics Corporation
NYSE · Healthcare · Medical Instruments & Supplies
Updated
When is HAE's next earnings date?
Haemonetics Corporation (HAE) is expected to report Q2 2027 earnings on Thursday, November 5, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.29 on revenue of $345.1M.
How did HAE do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q1 2027), Haemonetics Corporation posted EPS of $1.14 versus the $1.08 estimate, a beat of 4.6%. Revenue was $339.4M against a $327.9M estimate. The stock's 1-day post-earnings move was +1.7%.
How much does HAE stock move after earnings?
HAE beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.9% (up or down) in the day after earnings.
About Haemonetics Corporation
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q1 2027 | 1.08 | 1.14 | +4.59% | $339.4M | ✅ Beat | +1.70% | +9.26% | +23.03% |
| 2026-05-07 | Q4 2026 | 1.27 | 1.29 | +1.57% | $346.4M | ✅ Beat | +3.23% | +8.24% | +35.33% |
| 2026-02-05 | Q3 2026 | 1.26 | 1.31 | +3.97% | $339.0M | ✅ Beat | -1.41% | -12.81% | -2.76% |
| 2025-11-06 | Q2 2026 | 1.11 | 1.27 | +14.41% | $327.3M | ✅ Beat | +32.31% | +44.16% | +65.50% |
| 2025-02-06 | Q3 2025 | 1.17 | 1.19 | +1.71% | $348.5M | ✅ Beat | -11.58% | -13.94% | -3.57% |
| 2024-11-07 | Q2 2025 | 1.07 | 1.12 | +4.67% | $345.5M | ✅ Beat | +10.71% | +17.43% | +3.88% |
| 2024-05-09 | Q4 2024 | 0.89 | 0.90 | +1.12% | $343.3M | ✅ Beat | -0.70% | +3.47% | -8.19% |
| 2024-02-08 | Q3 2024 | 0.94 | 1.04 | +10.64% | $336.3M | ✅ Beat | +1.30% | -7.61% | +3.24% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q1 FY27 · $339.4M total
| Segment | Share | Revenue | YoY | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 76.0% | $257.8M | +6.4% | $256.1M | $257.7M | $248.3M | $242.4M |
| Europe | 13.4% | $45.5M | +11.4% | $42.0M | $44.2M | $42.3M | $40.9M |
| Asia | 5.9% | $20.2M | -6.9% | $25.8M | $25.6M | $21.2M | $21.6M |
| JAPAN | 3.8% | $12.9M | -5.8% | $16.4M | $16.2M | $16.1M | $13.6M |
| Other Country or Region | 0.9% | $3.0M | +6.2% | $5.3M | $4.9M | $2.8M | $2.8M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.